CU23716A1 - Péptido antagonista de la actividad de la interleucina-15 - Google Patents
Péptido antagonista de la actividad de la interleucina-15Info
- Publication number
- CU23716A1 CU23716A1 CU20080184A CU20080184A CU23716A1 CU 23716 A1 CU23716 A1 CU 23716A1 CU 20080184 A CU20080184 A CU 20080184A CU 20080184 A CU20080184 A CU 20080184A CU 23716 A1 CU23716 A1 CU 23716A1
- Authority
- CU
- Cuba
- Prior art keywords
- 15ralfa
- peptide
- activity
- interleucina
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se relaciona con la rama de la farmacología molecular, en particular con un péptido derivado de la secuencia de la Interleucina-15 (iL-15), que fue optimizado para inhibir la actividad biológica de esta molécula. En la presente invención se muestra que el péptido, al unirse a la subunidad alfa del receptor (IL-15Ralfa), inhibe la proliferación de células T inducida por la IL-15, la inducción de Factor de Necrosis Tumoral alfa (TNFalfa) por IL-15, y la expresión de la IL-8 e IL-6 por la IL-15Ralfa. La invención se relaciona, además, con el uso del péptido en el tratamiento de patologías donde la expresión anormal de la IL-15 o IL-15Ralfa está relacionada con el curso de la enfermedad, como artritis reumatoide (AR) y el cáncer de próstata.
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20080184A CU23716A1 (es) | 2008-09-30 | 2008-09-30 | Péptido antagonista de la actividad de la interleucina-15 |
AU2009298304A AU2009298304A1 (en) | 2008-09-30 | 2009-09-30 | Peptide antagonist of interleukin-15 activity |
RU2011117356/04A RU2506270C2 (ru) | 2008-09-30 | 2009-09-30 | Пептид-антагонист активности интерлейкина-15 |
CA2738744A CA2738744A1 (en) | 2008-09-30 | 2009-09-30 | Peptide antagonist of interleukin-15 activity |
US13/120,855 US8431524B2 (en) | 2008-09-30 | 2009-09-30 | Peptide antagonist of interleukin-15 activity |
KR1020117008431A KR20110095238A (ko) | 2008-09-30 | 2009-09-30 | 인터류킨-15 활성의 펩티드 안타고니스트 |
JP2011528178A JP2012503976A (ja) | 2008-09-30 | 2009-09-30 | インターロイキン−15活性のペプチドアンタゴニスト |
PCT/CU2009/000006 WO2010037351A1 (es) | 2008-09-30 | 2009-09-30 | Péptido antagonista de la actividad de la interleucina - 15 |
CN200980141683XA CN102203118B (zh) | 2008-09-30 | 2009-09-30 | 白介素-15活性的肽拮抗剂 |
MX2011003366A MX2011003366A (es) | 2008-09-30 | 2009-09-30 | Peptido antagonista de la actividad de la interleucina-15. |
EP09748938A EP2354152A1 (en) | 2008-09-30 | 2009-09-30 | Peptide antagonist of interleukin-15 activity |
ZA2011/02330A ZA201102330B (en) | 2008-09-30 | 2011-03-29 | Peptide antagonist of interleukin-15 activity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20080184A CU23716A1 (es) | 2008-09-30 | 2008-09-30 | Péptido antagonista de la actividad de la interleucina-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CU23716A1 true CU23716A1 (es) | 2011-10-05 |
Family
ID=41611190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU20080184A CU23716A1 (es) | 2008-09-30 | 2008-09-30 | Péptido antagonista de la actividad de la interleucina-15 |
Country Status (12)
Country | Link |
---|---|
US (1) | US8431524B2 (es) |
EP (1) | EP2354152A1 (es) |
JP (1) | JP2012503976A (es) |
KR (1) | KR20110095238A (es) |
CN (1) | CN102203118B (es) |
AU (1) | AU2009298304A1 (es) |
CA (1) | CA2738744A1 (es) |
CU (1) | CU23716A1 (es) |
MX (1) | MX2011003366A (es) |
RU (1) | RU2506270C2 (es) |
WO (1) | WO2010037351A1 (es) |
ZA (1) | ZA201102330B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120027948A1 (en) * | 2009-04-07 | 2012-02-02 | Basf Se | Composition for metal plating comprising suppressing agent for void free submicron feature filling |
MY158203A (en) * | 2009-04-07 | 2016-09-15 | Basf Se | Composition for metal plating comprising suppressing agent for void free submicron feature filling |
PL404174A1 (pl) | 2013-05-31 | 2014-12-08 | Warszawski Uniwersytet Medyczny | Zastosowanie pochodnych aminowych jako inhibitorów aktywności interleukiny 15 |
PL404138A1 (pl) | 2013-05-31 | 2014-12-08 | Warszawski Uniwersytet Medyczny | Pochodne kwasu benzoesowego jako inhibitory receptora IL-15Rα |
PL405505A1 (pl) * | 2013-09-30 | 2015-04-13 | Warszawski Uniwersytet Medyczny | Zastosowanie pochodnej kwasu diaminodikarboksylowego jako inhibitora aktywności biologicznej IL-15 I IL-2 |
PL405506A1 (pl) | 2013-09-30 | 2015-04-13 | Warszawski Uniwersytet Medyczny | Zastosowanie pochodnej kwasu 7-aminocefalosporanowego jako inhibitora aktywności biologicznej IL-15 i IL-2 |
US20160039876A1 (en) | 2014-03-28 | 2016-02-11 | Claresa Levetan | Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide |
CU24546B1 (es) * | 2016-12-30 | 2021-09-07 | Ct Ingenieria Genetica Biotecnologia | Composición vacunal que comprende un mutante de la interleucina-15 humana |
CU24545B1 (es) * | 2017-12-29 | 2021-09-07 | Ct Ingenieria Genetica Biotecnologia | Péptido antagonista de la actividad de la interleucina-15 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5795966A (en) | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
US7008624B1 (en) * | 1995-02-22 | 2006-03-07 | Immunex Corporation | Antagonists of interleukin-15 |
CA2252557A1 (en) | 1996-04-26 | 1997-11-06 | Beth Israel Deaconess Medical Center, Inc. | Antagonists of interleukin-15 |
KR100224383B1 (ko) * | 1996-09-09 | 1999-10-15 | 윤덕용 | 거머린에서 유도된 단백질분해효소 억제활성을지닌 펩타이드 |
WO2001002003A1 (en) * | 1999-07-06 | 2001-01-11 | Bulfone Paus Silvia | Method of treating psoriasis with il-15 antagonist |
JP3951676B2 (ja) * | 2001-11-13 | 2007-08-01 | 住友電気工業株式会社 | オリゴペプチド |
RS51829B (sr) | 2001-08-23 | 2012-02-29 | Genmab A/S. | Ljudska antitela specifična za interleukin 15 (il-15) |
AU2003247848B2 (en) * | 2002-07-02 | 2006-12-21 | The Board Of Regents, The University Of Texas System | Thrombin peptide derivative dimers |
JP5744369B2 (ja) * | 2004-02-27 | 2015-07-08 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | IL15−Rα用IL−15結合部位およびアゴニスト/アンタゴニスト活性を有する特異的IL−15突然変異体 |
CU23472A1 (es) * | 2004-09-17 | 2009-12-17 | Ct Ingenieria Genetica Biotech | Péptido antagonista de la interleucina-15 |
-
2008
- 2008-09-30 CU CU20080184A patent/CU23716A1/es not_active IP Right Cessation
-
2009
- 2009-09-30 AU AU2009298304A patent/AU2009298304A1/en not_active Abandoned
- 2009-09-30 CN CN200980141683XA patent/CN102203118B/zh not_active Expired - Fee Related
- 2009-09-30 CA CA2738744A patent/CA2738744A1/en not_active Abandoned
- 2009-09-30 RU RU2011117356/04A patent/RU2506270C2/ru not_active IP Right Cessation
- 2009-09-30 KR KR1020117008431A patent/KR20110095238A/ko not_active Application Discontinuation
- 2009-09-30 EP EP09748938A patent/EP2354152A1/en not_active Withdrawn
- 2009-09-30 MX MX2011003366A patent/MX2011003366A/es active IP Right Grant
- 2009-09-30 US US13/120,855 patent/US8431524B2/en not_active Expired - Fee Related
- 2009-09-30 JP JP2011528178A patent/JP2012503976A/ja active Pending
- 2009-09-30 WO PCT/CU2009/000006 patent/WO2010037351A1/es active Application Filing
-
2011
- 2011-03-29 ZA ZA2011/02330A patent/ZA201102330B/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2010037351A1 (es) | 2010-04-08 |
CN102203118B (zh) | 2013-07-10 |
JP2012503976A (ja) | 2012-02-16 |
KR20110095238A (ko) | 2011-08-24 |
CN102203118A (zh) | 2011-09-28 |
US20110251140A1 (en) | 2011-10-13 |
RU2011117356A (ru) | 2012-11-10 |
MX2011003366A (es) | 2011-07-29 |
RU2506270C2 (ru) | 2014-02-10 |
AU2009298304A1 (en) | 2010-04-08 |
EP2354152A1 (en) | 2011-08-10 |
ZA201102330B (en) | 2011-12-28 |
CA2738744A1 (en) | 2010-04-08 |
US8431524B2 (en) | 2013-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU23716A1 (es) | Péptido antagonista de la actividad de la interleucina-15 | |
AR051924A1 (es) | Peptido antagonista de la interleucina -15 | |
CY1118952T1 (el) | Εξανθρωπισμενο il-6 και υποδοχεας il-6 | |
CL2009000618A1 (es) | Uso de anticuerpo monoclonal humanizado th1, que reconoce el dominio 1 del cd6 humano, para preparar un medicamento útil en el tratamiento de la diabetes tipo-1. | |
HN2011001210A (es) | Anticuerpos humanos de alta afinidad para el receptor il-4 humano | |
GT200900263A (es) | Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cancer | |
AR061568A1 (es) | Compuestos | |
CL2008003119A1 (es) | Compuestos derivados de piridina o piridazina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de un estado inflamatorio y/o autoinmune tal como artritis reumatoide. | |
AR061230A1 (es) | Prolongacion de la supervivencia de pacientes con cancer con niveles elevados de egf o tgf-alfa | |
CL2012001627A1 (es) | Compuestos derivados de 1,3-tiazol-fenilaminopirimidinas, inhibidores de syk; composición farmacéutica; y su uso para el tratamiento de la artritis reumatoide y cancer. | |
ECSP11011450A (es) | ANTICUERPOS ANTI-TNF-a Y SUS USOS | |
ECSP11010748A (es) | Antagonistas específicos del receptor fgf-r4 | |
CL2011002942A1 (es) | Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer. | |
ECSP10010475A (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
UA113388C2 (xx) | ЗАСТОСУВАННЯ АНТИТІЛА ПРОТИ с-МЕТ | |
DOP2013000044A (es) | Anticuerpos para el receptor del factor de crecimiento epidermico 3 (her3) | |
EA201290557A1 (ru) | Пептидный аналог оксинтомодулина | |
CL2011003229A1 (es) | Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer. | |
PE20140382A1 (es) | Polipeptidos derivados de la il-2 con actividad agonista para la terapia del cancer e infecciones cronicas | |
TW200942552A (en) | Combination therapy with c-Met and HER antagonists | |
UY30932A1 (es) | Miembros ligantes, especialmente moléculas de anticuerpo, para cxcl13, útiles para tratamiento de trastornos asociados con cxcl13, métodos productivos, composiciones y aplicaciones. | |
BR112012011528A2 (pt) | métodos para inibir uma proteína quinase e para tratar uma doença associada com atividade de quinase, e, composto | |
BR112014002817A2 (pt) | Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62 | |
IN2012DN03338A (es) | ||
EA201890598A2 (ru) | Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant of patent | ||
FD | Lapse (for not paying fees) |